Dossier assessment
Ledipasvir/sofosbuvir (hepatitis C) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ledipasvir/sofosbuvir (hepatitis C) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ledipasvir/sofosbuvir (hepatitis C) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Chronic hepatitis C in pretreated and treatment-naive adolescents
Genotype 1 with and without pretreatment: hint of a non-quantifiable added benefit; other genotypes: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2018-02-15 A G-BA decision was published.
Project details
- Project no.
- A17-41
- Commission
- Commission awarded on 16.08.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed